Announcements Trials
Browse Landscape

Phase

Phase 1 2

Status

Withdrawn 1Completed 1

Sponsor Class

OTHER 6NIH 5INDUSTRY 2

Study Type

Interventional 2

Sponsor

Cancer Type

Dermatologic 97Thoracic 60Genitourinary 38Gastrointestinal 34Other solid neoplasm 18Tumor-Agnostic 13Head & Neck 12Gynecologic 9Breast 9Sarcoma 7Lymphoid 5Myeloid 2CNS 2Plasma cell 1Other hematologic neoplasm 1Endocrine 1

Conditions

Myeloproliferative Disorders 1Leukemia, Myelogenous, Chronic, BCR-ABL Positive 1

Interventions

Azacitidine 68nilotinib 50Imatinib Mesylate 50ruxolitinib 42Dasatinib 25venetoclax 22Decitabine 20bosutinib 18asciminib 17Cytarabine 15ponatinib 10decitabine and cedazuridine drug combination 10AP 1903 reagent 10Cyclophosphamide 9fludarabine 8Hydroxyurea 8navitoclax 6ON 01910 6sabatolimab 5pevonedistat 5mocetinostat 5luspatercept 5itacitinib 5imetelstat 5givinostat hydrochloride 5givinostat 5fludarabine phosphate 5avapritinib 5Mycophenolic Acid 5Lenalidomide 5

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
INDUSTRY × Ipilimumab × Myeloid × Clear all
NCT05444530 2025-07-20

A Study of VAC85135, a Neoantigen Vaccine Regimen, Concurrently Administered With Ipilimumab for the Treatment of Myeloproliferative Neoplasms

Janssen Research & Development, LLC

Phase 1 Completed
14 enrolled
Myeloid

Myeloproliferative Disorders

NCT00732186 2016-02-17

Study of Ipilimumab and Dasatinib Combination Therapy in Patients With Chronic or Accelerated Chronic Myeloid Leukemia

Bristol-Myers Squibb

Phase 1 Withdrawn
MyeloidOther hematologic neoplasm

Leukemia, Myelogenous, Chronic, BCR-ABL Positive

Data powered by HemOnc (CC BY 4.0) Colophon âš¡